2,683 results on '"mirabegron"'
Search Results
2. The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists
3. Activation of Brown Adipose Tissue Metabolism Using Mirabegron (GB9)
4. Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate
5. A Study of Mirabegron in Young Children With Neurogenic Detrusor Overactivity
6. Study of ONO-8577 in Patients With Overactive Bladder
7. MIrabegron and Physiological Function in Cold Environments
8. ADRB3 Signaling Pathway in Human Adipose Tissue
9. Management of OAB in Female Patients .
10. Effect of Behavioral Sleep Intervention on Lower Urinary Tract Symptoms in Older Women (SLAB)
11. A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)
12. Does Mirabegron Increase the Body Heat Generated by the Nervous System
13. Efficacy and Safety of Mirabegron in Intracerebral Hemorrhage
14. Using Mirabegron to Increase BP in Patients With POTS (RAISE BP)
15. A Multidisciplinary, Multimodal Bundled Care Approach to Chronic Pelvic Pain
16. Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder
17. Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy Adults
18. In vitro effects of β3‐adrenoceptor agonist mirabegron on the human ureter.
19. Fragility of overactive bladder medication clinical trials: A systematic review.
20. Dynamic phenotypic shifts and M2 receptor downregulation in bladder smooth muscle cells induced by mirabegron.
21. Posterior Tibial Nerve Stimulation With versus Without Mirabegron: A Randomized Controlled Trial.
22. Genetic Variation in CYP2D6 , UGT1A4 , SLC6A2 and SLCO1B1 Alters the Pharmacokinetics and Safety of Mirabegron.
23. Silencing of ultradian rhythms and metabolic depression during spontaneous daily torpor in Djungarian hamsters.
24. Intestinal Absorption Site-Guided Development and Evaluation of Oral Disintegrating Controlled Release Tablets of Mirabegron.
25. Comparative Approaches in Treating Double-J Stent Syndrome: Monotherapy or Combination Therapy?
26. An examination of Overactive Bladder Syndrome: present comprehension, methods of treatment, and innovative approaches.
27. To assess the effectiveness of Mirabegron in reducing urodynamic detrusor overstimulation in patients with Overactive Bladder Syndrome (OAB).
28. Ligand–Receptor Interactions and Structure–Function Relationships in Off-Target Binding of the β 3 -Adrenergic Agonist Mirabegron to α 1A -Adrenergic Receptors.
29. Therapeutic effectiveness and adverse drug reactions of mirabegron versus solifenacin in the treatment of overactive bladder syndrome.
30. Roles of β-adrenoceptor Subtypes and Therapeutics in Human Cardiovascular Disease: Heart Failure, Tachyarrhythmias and Other Cardiovascular Disorders
31. A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) (Dolphin)
32. Acupuncture Combined With Mirabegron in the Treatment of OAB (ACWMITTOOAB)
33. TReating Incontinence for Underlying Mental and Physical Health (TRIUMPH)
34. Mechanisms for Activation of Beige Adipose Tissue in Humans
35. Comparative Effectiveness of Initial OAB Treatment Options Among Older Women at High Risk of Falls
36. THE EFFECTS OF MIRABEGRON AND TAMSULOSIN FOR PATIENTS WITH URETERAL STENTS
37. Extracorporeal Magnetic Innervation in Combination With Mirabegron in the Treatment of Overactive Bladder
38. The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
39. Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple Sclerosis (MIRROR)
40. Relief of double-J stent-related symptoms: a comparison between mirabegron, tamsulosin and solifenacin
41. Relief of double-J stent-related symptoms: a comparison between mirabegron, tamsulosin and solifenacin.
42. Efficacy of transcutaneous electrical nerve stimulation combined with mirabegron therapy compared with mirabegron monotherapy for overactive bladder: a prospective randomized controlled study.
43. Nerve Growth Factor and Brain-Derived Neurotrophic Factor as Potential Biomarkers of Mirabegron Efficacy in Patients with Overactive Bladder Syndrome.
44. Pre-Steady-State and Steady-State Kinetic Analysis of Butyrylcholinesterase-Catalyzed Hydrolysis of Mirabegron, an Arylacylamide Drug.
45. Evaluation of the efficacy and safety of either or both mirabegron and silodosin, as a medical expulsive therapy for distal ureteric stones.
46. Efficacy and safety of pelvic floor magnetic stimulation combined with mirabegron in female patients with refractory overactive bladder: a prospective study.
47. Comparing silodosin and mirabegron as medical expulsive therapy for distal ureteral calculus: a prospective, randomised study.
48. Safety and effectiveness of mirabegron for children and adolescents with refractory idiopathic overactive bladder for improving urinary symptoms: a systematic review.
49. Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database.
50. An individual participant meta‐analysis of mirabegron in multiple sclerosis and spinal cord injury.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.